Geron to Present at the H.C. Wainwright Global Investment Conference
18 May 2022 - 6:30AM
Business Wire
Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical
company focused on the development and commercialization of
treatments for hematologic malignancies, today announced that John
A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer,
plans to present a company overview at the H.C. Wainwright Global
Investment Conference. The presentation will be available as an
on-demand session beginning May 24, 2022 at 7 a.m. ET.
A webcast of the presentation will be available through the
Investor Relations section of Geron’s website under Events.
Following the presentation, the webcast will be archived and
available for replay for a period of 30 days.
About Geron
Geron is a late-stage clinical biopharmaceutical company focused
on the development and potential commercialization of a
first-in-class telomerase inhibitor, imetelstat, in hematologic
malignancies. The Company currently is conducting two Phase 3
clinical trials: IMerge in lower risk myelodysplastic syndromes and
IMpactMF in refractory myelofibrosis.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220517005151/en/
Aron Feingold Investor and Media Relations investor@geron.com
media@geron.com
Geron (NASDAQ:GERN)
Historical Stock Chart
From Apr 2024 to May 2024
Geron (NASDAQ:GERN)
Historical Stock Chart
From May 2023 to May 2024